GBT Announces New Employment Inducement Grants
July 08 2020 - 8:00AM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today
announced that on July 1, 2020, the compensation committee of GBT’s
board of directors granted 11 new employees restricted stock units
for an aggregate of 27,550 shares of the company’s common stock.
These awards were made under GBT’s Amended and Restated 2017
Inducement Equity Plan (the Plan).
The above-described awards were each granted as an inducement
material to the employees entering into employment with the company
in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted
pursuant to the terms of the Plan. The 2017 Inducement Equity Plan
was adopted by GBT’s board of directors in January 2017 and has
been amended and restated from time to time.
About Global Blood TherapeuticsGlobal Blood
Therapeutics (GBT) is a biopharmaceutical company dedicated to the
discovery, development, and delivery of life-changing treatments
that provide hope to underserved patient communities. Founded in
2011, GBT is delivering on its goal to transform the treatment and
care of sickle cell disease (SCD), a lifelong, devastating
inherited blood disorder. The company has introduced Oxbryta®
(voxelotor), the first FDA-approved treatment that directly
inhibits sickle hemoglobin polymerization, the root cause of red
blood cell sickling in SCD. GBT is also advancing its pipeline
program in SCD with inclacumab, a p-selectin inhibitor in
development to address pain crises associated with the disease. In
addition, GBT’s drug discovery teams are working on new targets to
develop the next generation of treatments for SCD. To learn more,
please visit www.gbt.com and follow the company on Twitter
@GBT_news.
Contact Information:Steven Immergut
(media)650-410-3258simmergut@gbt.com
Stephanie Yao (investors)650-741-7730syao@gbt.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Apr 2023 to Apr 2024